stannsoporfin
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nutritional and Metabolic Diseases
Conditions
Nutritional and Metabolic Diseases
Trial Timeline
May 1, 2002 → Feb 1, 2013
NCT ID
NCT02685137About stannsoporfin
stannsoporfin is a phase 3 stage product being developed by Mallinckrodt Pharmaceuticals for Nutritional and Metabolic Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT02685137. Target conditions include Nutritional and Metabolic Diseases.
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00850993 | Phase 2 | Terminated |
| NCT02685137 | Phase 3 | Completed |
Competing Products
2 competing products in Nutritional and Metabolic Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| rasburicase (SR29142) | Sanofi | Phase 2 | 35 |
| ClinOleic (Baxter Healthcare, Deerfield, IL, USA) | Baxter | Phase 1 | 22 |